IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results - Seite 2

Financial Results:

Total revenues for the three-month period ended December 31, 2023 amounted to $426,000, an increase of $253,000, or 146%, compared to $173,000 for the three-month period ended December 31, 2022. The change is mainly attributable to an increase in research and development (“R&D”) revenues. Operating costs and expenses were $2.4 million for the fourth quarter of 2023, versus $2.7 million for the corresponding three-month period of 2022. For Q4-2023, the Company had an operating loss of $2.0 million, down from $2.5 million for the comparable period of 2022. Net comprehensive loss was $1.7 million, or $0.01 per basic and diluted share, for the fourth quarter of 2023, compared to net comprehensive loss of $2.3 million, or $0.01 per basic and diluted share, for the comparable period of 2022.

Total revenues for the twelve-month period ended December 31, 2023 amounted to $1.04 million, representing an increase of $89,000, or 6%, compared to $950,000 for the year ended December 31, 2022. Operating costs and expenses were $10.5 million for the full year 2023, versus $10.4 million for the corresponding twelve-month period of 2022. For the twelve-month period of 2023, the Company had an operating loss of $9.5 million, compared to an operating loss of $9.4 million for the comparable period of 2022. Net comprehensive loss was $10.1 million, or $0.06 per basic and diluted share, for the twelve-month period of 2023, compared to net comprehensive loss of $11.6 million, or $0.07 per basic and diluted share, for the comparable period of 2022.

As at December 31, 2023, the Company's cash and short-term investments totalled $2.3 million. Subsequent to year-end, IntelGenx announced the launch of the Regulation A Share Offering and received $1 million pursuant to its Loan Agreement with atai.

Annual Filings:

The Company's annual report on Form 10-K and financial statements for the year ended December 31, 2023, as well as the 2024 Proxy Statement, will be filed with the United States Securities and Exchange Commission and the Canadian Securities regulatory authorities today, March 21, 2024.

Conference Call Details:

IntelGenx will host a conference call to discuss these 2022 fourth quarter and full year financial results today at 8:30 a.m. ET. The dial-in number for the conference call is [phone] (Canada and the United States) or [phone] (International); access code 321268. The call will be also be webcast live and archived on the Company's website at www.intelgenx.com under "Webcasts" in the Investors section.